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Nitric Oxide and 
Osteoporosis:
What a Gas!
Sophie Jamal, MD, PhD, FRCPC
Associate Professor of Medicine
University of Toronto
Outline
? Pathophysiology of osteoporosis
? Nitric oxide and bone turnover
? The effects of isosorbide mononitrate on 
markers of bone turnover
? The effects of nitroglycerin on bone 
turnover geometry and strength
Effect of estrogen and transdermal 
NTG on BMD (Wimalawansa et al Bone 1996)
Treatment group Percent increase in 
BMD (L2-L4) over 6 
weeks
Sham operated 25% ? 2%
Ovariectomized rats 8% ? 3%
Ovariectomized + Estrogen 27% ? 5%*
Ovariectomized + NTG 20% ? 3%**
Ovariectomized + E + NTG 22% ? 2%*
*different than ovariectomized rats at p<0.005
** different than ovariectomized rats at p<0.02
Low bone mineral density 
(BMD): a risk factor for 
osteoporotic fractures
? Relationship between hip fracture and hip 
BMD: 2.6 RR/SD
? BMD = bone formation - bone resorption
? Increased bone resorption at menopause 
? Nitric oxide may contribute to 
postmenopausal bone loss
Sources of nitric oxide
L-arginine + O2 Nitric Oxide
Nitric Oxide 
Synthase
(NOS)
Endogenous
Isosorbide Mononitrate
Isosorbide Dinitrate
Nitroglycerin
Nitrate & Nitrite
Exogenous
Bone cells make nitric oxide
? Two cell types involved in bone remodeling:
?Osteoclasts ? bone resorption
?Osteoblasts ? bone formation
? Osteoblasts produce enitric oxide synthase
? Estrogen and mechanical strain produce
initric oxide synthase
NO influences osteoclasts
?Nitric oxide has a biphasic effect on 
osteoclasts
?Low levels enhance osteoclast activity 
and differentiation
?High levels inhibit osteoclast activity and 
differentiation
NO may mediate effects via OPG
?High levels of nitric oxide activate OPG
? Low levels of nitric oxide activate OPGL
BONE
Bone resorption depends on the 
balance of OPG and OPGL
OPGL OPG
OPG
Osteoclast 
Precursor
Bone
Osteoblasts
Osteoclast
RANK
RANK
Hormones OPG Ligand
The OPG/OPGL/RANK axis
OPG
NO
What about osteoblasts?
? Limited data
?Biphasic activity:
?High levels of NO stimulate 
osteoblast activity
?Low levels of NO inhibit osteoblast 
activity
In vitro data: a summary
? Nitric oxide stimulates OPG 
?OPG binds to OPGL
?Prevents binding of OPGL to RANK
?Decreased osteoclast activity (bone 
resorption)
? Issues
? Is the effect similar with nitric oxide donors?
?Does the decrease in bone resorption lead to 
increased bone mineral density?
Effect of estrogen and transdermal 
NTG on BMD (Wimalawansa et al Bone 1996)
Treatment group Percent increase in 
BMD (L2-L4) over 6 
weeks
Sham operated 25% ? 2%
Ovariectomized rats 8% ? 3%
Ovariectomized + Estrogen 27% ? 5%*
Ovariectomized + NTG 20% ? 3%**
Ovariectomized + E + NTG 22% ? 2%*
*different than ovariectomized rats at p<0.005
** different than ovariectomized rats at p<0.02
Effect of frequency of administration
Treatment Group (n = 5) Change in Spine 
BMD
Sham operated 6.3 % ? 5.3 *
Ovariectomy (OVX) – 2.5 % ? 2.0
OVX + estrogen 5.9 % ? 3.4*
OVX + 0.2 mg  NTG once a day 6.2 % ? 2.8*
OVX + 0.2 mg  NTG twice a day 1.9 % ? 2.1
OVX + 0.2 mg  NTG  three times a day – 0.2 % ? 3.3
Wimalawansa SJ et al.  JBMR 2000
Does NO play a role in menopause?
? Menopause is characterized by:
?Increased bone resorption
?Low circulating estrogen
?Low levels of nitric oxide
? Treatment with HRT increases nitric oxide 
and decreases bone resorption
Nitrates and bone mineral density -
1996
? SOF study (n = 6201) (Jamal SA et al JBMR 1998)
?BMD at heel and spine
?Daily users = nonusers
? Intermittent users higher
? Open label trial (n = 16) (Wimalawansa SJ, JBMR 2000).
? Conjugated estrogen or transdermal 
nitroglycerin
? Equal BMD at one year
Percent difference in BMD, nitrate     
users compared with nonusers
Daily vs.
Nonusers
(n = 317, 5810)
(95% CI)
Intermittent vs. 
Nonusers
(n=74,5810)
(95% CI)
Hip BMD
Unadjusted  0 (-2.7 to 1.4) 0 (-4.1 to 4.1)
Adjusted 1.3 (0.14 to 4.1) 2.6 (0.4 to 6.8)
Heel BMD
Unadjusted -2.6 (-5.3 to 0) 0 (-5.3 to 7.9)
Adjusted 0 (-2.6 to 2.6) 5.3 (2.6 to 11)
Jamal SA, et al.  JBMR 1998
Nitrates and Fractures
? 124,655 subjects with fractures (cases)
? 373,962 controls
? Self-reported nitrate use 1995-200
? Nitrate use associated with decreased 
fracture risk:
?Any fracture: OR = 0.89 (0.86 to 0.92)
?Hip fracture: OR = 0. 85 (0.79 to 0.92)
Rejnmark L et al, JBMR 2006
Findings so far...
?Use of nitrates may be associated 
with increases in BMD
?Use of nitrates may decrease risk of 
fractures
? Tolerance to nitrates might exist
The second study- 1998
? To determine the effects of isosorbide 
on markers of bone turnover
? To assess if there is a dose response
?Applied for funding 1998, received 
funding 1999
?Completed study 2002
?Published 2004
Study design
Months
Phase I
0 1 2 3
Vitamin D 400 IU
Calcium 500 mg
Blood
Urine
ISMO 5 mg 
or ISMO 20 mg
or Placebo
4 5 6
Blood
Urine
Phase II
Study subjects
? Inclusion Criteria:
?Postmenopausal women, 50 to 80 yrs
?Osteopenia or normal BMD at femoral neck
? Exclusion Criteria:
?Low trauma fracture (hip, wrist, spine)
?Active bone disease
?Treatment for osteoporosis
?Treatment with steroids
?Heart disease
Markers of bone turnover
? 2 classes of biochemical markers: 
?Bone formation (osteoblast activity)
?Bone resorption (osteoclast activity)
? Resorption and formation are 
coupled 
?May be different with ISMO
Why biochemical markers?
?Markers of bone turnover are 
correlated with bone mineral density
?Substantial changes in markers can 
be seen within 3 months of treatment
?Minimizes costs
?Minimizes adverse events 
451 women screened
245 eligible
146 women : calcium and vitamin D 
144 women randomized
48 : placebo
4 drop outs
no samples 
44 : placebo
49 : 5 mg ISMO
11 drop outs
6 samples
44 : 5 mg ISMO
206  ineligible
47 : 20 mg ISMO
10 drop outs
5 samples
42 : 20 mg ISMO
99 did not participate
2 did not return
Subject characteristics
22 ? 6.623 ? 6.325 ? 6.9BSAP (IU/L)
82 ? 71.579 ? 61.862 ? 65.9NTX (nmol BCE/mmol 
Cr)
10 ? 612 ? 1013 ? 8Years since 
menopause
7 (15%)5 (10%)5 (10%)Current smoker
44 (94%)44 (90%)45 (94%)Caucasian 
74 ? 1570 ? 1574 ? 16Weight  (kg)
59 ? 5.559 ? 7.562 ? 7.0Age (yrs)
20 mg ISMO
(n = 47)
5 mg ISMO
(n = 49)
Placebo 
(n = 48)
Jamal SA et al, JBMR 2004
ISMO decreased bone resorption 
markers
20 mg 
-36.3
-45.4
-60
-40
-20
0
20
40
NTX
Percent
change
vs. 
placebo
5 mg
p = 0.0002           p = 0.0001
ISMO increased bone formation 
markers
20 mg 
15.9 23.3
-60
-40
-20
0
20
40
BSAP
Percent
change
vs. 
placebo
5 mg
p = 0. 005      p = 0.001
Headaches were common
Placebo
(n = 48) 
5 mg ISMO
(n = 49)
20 mg ISMO
(n = 47)
Discontinued study 4 11 10
D/C due to  headache 2 7 9
Limitations
?Generalizability
?Study population healthy Caucasians
?Duration of study was 12 weeks
?Studies with BMD and fracture end 
points are needed
Implications of our findings
? Decrease in NTx similar to bisphosphonates
? 40% decrease in NTx: 30% decrease in fracture 
risk
? We also found an increase in formation markers-
? ?greater fracture reduction than with 
antiresorptives
? Headache may limit the use of this drug:
? 10% of women had headaches, 75% of drop outs
? 4X more common in women randomized to ISMO
? Higher than reported in CV literature
? ?Less headaches with transdermal NTG
The third study
? Applied for funding March 2004- rejected
? Reapplied for funding March 2005
? Funded October 2005
? Completed Trial March 2010
? 2 part randomized controlled trial:
?3 week cross over study to compare 
tolerability of NTG and ISMO
?2 year study of best tolerated nitrate
? Outcomes in 2 year study:
?Change in lumbar spine and hip BMD
?Change in bone turnover markers
?Changes in trabecular bone with pQCT
Study Hypothesis
15 mg of Nitroglycerin, applied once 
daily, will lead to uncoupling of bone 
turnover, increases in bone mineral 
density and bone geometry, compared 
with placebo.
Study Design
?One week run in phase
?24 month duration
?End points:
?Bone turnover markers
?Bone mineral density
?pQCT 
Study Subjects
?Inclusion: 
?Postmenopausal ? 50 years 
?L spine T score between 0 and -2.0
?Exclusion:
?Migraine headaches
?Already taking nitrates
?SBP ? 100 mm Hg, DBP ?110 mm Hg
Statistical Analyses
?Primary Endpoint:
?Lumbar spine BMD
?Secondary Endpoints:
?Hip BMD 
?pQCT at radius and tibia
?B-ALP, NTX (log transformed data)
- L -
Assessed for 
eligibility (n=1526)
Enrolled in 1 week run in
phase (n = 400)
-
Discontinued study (n= 157)
Headaches (93)
Headaches and nausea (11)
Randomized (n = 243)
Nitroglycerin ( n =126)
Analysed:
Data on 116 at 24 m
Discontinued intervention ( n = 30)
Headaches ( n =7)
No follow up data ( n = 8)
Analysed:
Data on 109 at 24m
Placebo ( n = 117)
Discontinued intervention ( n =15)
Headaches ( n = 2)
Lost to follow up ( n = 6)
Excluded (n = 1283)
Did not meet inclusion criteria (541)
Declined to participate (585)
NTG 
Ointment
N = 126
Placebo
N = 117
Age (yrs) 61.3 61.9 
Weight (kg) 70.3 70.9 
Vitamin D (IU/day) 783. 2 753.2
Calcium (mg/day) 1548.8 1565.6 
L Spine T-score -0.9 -1.1 
Nitrate=126
Placebo=117
35.9%
(34.4 to 37.4)


6.7% 
(5.2 to 8.2)
7.0%
(5.5-8.5)
6.2%
(5.2 to 7.3)
PQCT of the Radius
Measurement % Difference (95%CI)
Trabecular density 11.9 (8.1 to 15.7)
Cortical thickness 13.9 (6.0 to 21.7)
Cortical density 2.2 (0.6 to 3.7)
Cortical area 10.6 (6.9 to 14.3)
Periosteal circumference 7.4 (4.3 to 10.4)
Indices of Radial Bone Strength
Measurement % difference (95%CI)
Polar Section Modulus 10.7 (7.5 to 13.8)
Polar Moment of 
Inertia
7.3 (4.6 to 10.1)
PQCT of the Tibia
Measurement % Difference (95%CI)
Trabecular density 8.5 (4.3 to 12.7)
Cortical thickness 24.6 (18.9 to 30.4)
Cortical density 1.5 (0.8 to 2.3)
Cortical area 10.0 (5.2 to 15.0)
Periosteal circumference 2.9 (1.0 to 6.8)
Indices of Tibial Bone 
Strength
Measurement % difference (95%CI)
Polar Section Modulus 9.8 (0.2 to 19.4)
Polar Moment of 
Inertia
14.5 (3.2 to 25.8)
Headaches
Run In 
Phase
400 enrolled, 104 did not 
continue
Treatment Nitroglycerin Placebo
d/c at 12 
months
7 (23.3%) 2 (13.3%)
1 month 35% 5.4%
12 months 5.3% 0.9%
24 months 2% 0
Nitroglyceri
n
Placebo
Serious Adverse events 5 (4.2%) 5 (4.3%)
-Death 1 (1%) 0
Fractures 2 (1.6%) 2 (1.7%)
Conclusions
?Nitroglycerin uncouples bone turnover
?Improves BMD, geometry, indices of 
strength
?Inexpensive and widely available
?Initiation of treatment limited by headache
?The efficacy of nitroglycerin to reduce 
fracture risk should be tested in a clinical 
trial
